The purpose of this investigation was to compare the efficacy of colistin-based therapies in
extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A
retrospective study was conducted in 27 tertiary-care centers from January 2009 to August
2012. The primary end-point was 14-day survival, and the secondary end-points were
clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7%): colistin–
carbapenem (CC), 69 (32.2%): colistin–sulbactam (CS), and 43 (20.1%: tigecycline): colistin …

Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial
agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream
infections … Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other
antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii
bloodstream infections … Comparison of colistin-carbapenem, colistin-sulbactam, and
colistin plus other antibacterial agents for the treatment of extremely drug-resistant …